Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision BioSciences is supported by a differentiated ARCUS platform with two wholly owned clinical-stage programs that attack major unmet needs in HBV and DMD, giving it a high-risk, high-reward profile with meaningful upside if translation continues to track preclinical and early clinical signals. In HBV, PBGENE-HBV has delivered 38 doses across 16 patients and the first clinical evidence of direct cccDNA elimination, with 6/6 baseline-pgRNA-positive patients becoming undetectable and HBsAg declining in 15/15 evaluable patients, suggesting a potential finite-curative, source-control backbone rather than simple antigen suppression. In DMD, PBGENE-DMD’s single-AAV, near full-length dystrophin approach addresses up to ~60% of patients and has shown strong preclinical restoration and durable functional gains, while manufacturing and GLP safety data help de-risk the platform ahead of the imminent first-patient dosing.

Precision BioSciences is facing a fundamentally weak investment case because its lead HBV program still depends on an unsettled regulatory path, with investors cautious that pgRNA may not be accepted as a surrogate for cccDNA and that curative benefit cannot be validated until patients discontinue background NUCs. The company also carries substantial execution and financing risk, as the model assigns only a 20% probability of success to PBGENE-DMD and 40% to the partnered allogeneic CD19 CAR-T program, while assuming roughly $100M of gross equity raises in 2027E that could dilute shareholders. Although the analysis embeds ARCUS-related revenue starting in 2030 and a total firm value of about $1.5 billion, those long-dated assumptions rest on a 12% discount rate, a 6.0x terminal EBITDA multiple, and high clinical uncertainty that supports a negative outlook.